What are the Indian Academy of Pediatrics (IAP) guidelines for using antiemetic medications in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IAP Guidelines for Antiemetic Use in Children

The Indian Academy of Pediatrics (IAP) specific guidelines for antiemetic use are not available in the provided evidence; however, international pediatric antiemetic guidelines from ASCO, MASCC/ESMO, and other major societies provide the evidence-based framework that should guide practice in Indian pediatric settings.

Chemotherapy-Induced Nausea and Vomiting (CINV)

High Emetogenic Risk Chemotherapy

Pediatric patients receiving high-emetic-risk chemotherapy should receive a three-drug combination of a 5-HT3 receptor antagonist, dexamethasone, and aprepitant (or fosaprepitant). 1

  • 5-HT3 antagonist plus dexamethasone forms the backbone of prophylaxis 1
  • Addition of aprepitant significantly reduces moderate-to-severe vomiting (38% vs 72% in placebo arm, P=0.001) in the acute phase (0-24 hours) 1
  • Palonosetron (20 mcg/kg) may be superior to ondansetron for delayed emesis (0-120 hours) 1
  • Fosaprepitant combined with ondansetron and dexamethasone achieved 79% delayed-phase complete response vs 51% without fosaprepitant (P<0.001) 1

Key dosing considerations:

  • Children require higher weight-based doses of 5-HT3 antagonists than adults due to pharmacokinetic differences 1
  • Established doses: Ondansetron 5 mg/m² or 0.15 mg/kg; Granisetron 0.01 mg/kg or 10 mcg/kg once daily 1

Moderate Emetogenic Risk Chemotherapy

Pediatric patients receiving moderate-emetic-risk chemotherapy should receive a two-drug combination of a 5-HT3 receptor antagonist and dexamethasone. 1

  • This combination is more efficacious than 5-HT3 antagonist alone 1
  • For children unable to receive dexamethasone: Use 5-HT3 antagonist plus aprepitant (weak recommendation) 1

Low Emetogenic Risk Chemotherapy

Pediatric patients receiving low-emetic-risk chemotherapy should be offered ondansetron or granisetron alone. 1

  • No corticosteroid or NK1 antagonist needed 1

Minimal Emetogenic Risk Chemotherapy

No routine antiemetic prophylaxis should be administered for minimal-emetic-risk chemotherapy. 1

Acute Gastroenteritis

Primary Recommendation

Ondansetron is the only antiemetic with proven efficacy and safety for gastroenteritis-related vomiting in children. 2

A single oral dose of ondansetron should be administered to reduce:

  • Recurrent vomiting episodes 2, 3
  • Need for intravenous rehydration 2, 3
  • Hospital admissions 2, 3, 4

Evidence quality: High for cessation of vomiting; Moderate for preventing hospitalization 2

Agents to Avoid

Do NOT use the following antiemetics in pediatric gastroenteritis:

  • Promethazine, prochlorperazine, metoclopramide: Common and potentially dangerous side effects including extrapyramidal reactions 1, 4, 5
  • Dimenhydrinate: Only intervention worse than placebo for side effects 2
  • Domperidone: Insufficient safety evidence despite common use 3

Clinical Application

  • Ondansetron facilitates oral rehydration therapy success 3, 4, 5
  • Consider when vomiting hinders oral rehydration 5
  • Single-dose administration minimizes adverse event risk 4, 5

Special Populations and Situations

High-Dose Chemotherapy with Stem Cell Transplantation

Use 5-HT3 receptor antagonist combined with dexamethasone; consider adding aprepitant. 1

  • Olanzapine (10 mg) added to fosaprepitant, ondansetron, and dexamethasone improved complete response (55% vs 26%, P=0.003) in HCT patients 1

Multiday Chemotherapy

Administer antiemetics appropriate for the emetogenic risk class for each day of chemotherapy and for 2 days after. 1

Breakthrough Nausea/Vomiting Despite Prophylaxis

Systematic re-evaluation approach: 1

  1. Re-evaluate emetic risk, disease status, concurrent medications
  2. Verify optimal regimen for emetic risk category
  3. Consider adding lorazepam or alprazolam as adjunct
  4. Consider adding olanzapine or substituting high-dose IV metoclopramide for 5-HT3 antagonist

Important Caveats

  • Adjunctive agents (lorazepam, diphenhydramine) are useful adjuncts but NOT recommended as single-agent antiemetics 1
  • Complementary therapies: No published RCT data support recommendations for ginger or acupuncture-point stimulation 1
  • Agent equivalence: At equivalent doses, 5-HT3 antagonists (ondansetron, granisetron, dolasetron) have equivalent safety and efficacy for acute emesis 1
  • Limited pediatric-specific data exists for delayed and anticipatory emesis prevention 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Research

Antiemetic Drug Use in Children: What the Clinician Needs to Know.

Journal of pediatric gastroenterology and nutrition, 2019

Related Questions

What is the appropriate first‑line antiemetic for a child younger than two years?
What are the Indian Academy of Pediatrics (IAP) guidelines for the use of antiemetics in children with vomiting?
What does a normal bone‑density (dual‑energy X‑ray absorptiometry) result indicate and what management is recommended?
Is it safe to perform a living donor kidney transplant in a recipient who recently received a blood transfusion, and what immunologic evaluation is required?
In a minor with a life‑threatening condition and a 50 percent chance of survival whose mother refuses all intravenous (IV) and oral medications and the child is unvaccinated, what is the next appropriate step in management?
What are the advantages of using a combination of polymyxin B, ceftazidime‑avibactam, and aztreonam?
What is the appropriate treatment for a patient with massive left‑lung atelectasis and cystic bronchiectasis (destroyed lung), a heterogeneously enhancing ovoid density in the right upper lobe, right‑lung pulmonary tuberculosis, a large pericardial effusion, and minimal perihepatic ascites?
How should I manage low ferritin with a normal mean corpuscular volume?
What is the recommended treatment for a confirmed Group A Streptococcus pharyngitis?
How should levothyroxine be initiated and titrated for hypothyroidism, including dosing based on weight and age, and what target TSH and free T4 values should be aimed for?
What are the clinical uses of cefpodoxime (cefpodoxime proxetil)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question